Figures computed from official regulatory filings — .
Analysttarget 9 USD (+711%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 65.71% · institutions 5.77% · short 2.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cocrystal Pharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
43 buys2 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| FROST PHILLIP MD ET ALtrack record | Buy | $9.8K | conv 27 |
| FROST PHILLIP MD ET ALtrack record | Buy | $70.6K | conv 35 | SEC |
| SAPIRSTEIN JAMES | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $20K | conv 29 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $47.5K | conv 31 | SEC |
| Lee Sam | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kornberg Roger D. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FROST PHILLIP MD ET ALtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PFENNIGER RICHARD C JRtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martin James Joseph | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HASSAN FREDtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rubin Steven Dtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Japour Anthony J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $47.5K | conv 30 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $19.4K | conv 29 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $38.8K | conv 30 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $24.3K | conv 30 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $2.5K | conv 17 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $1.5K | conv 17 | SEC |
| FROST PHILLIP MD ET ALtrack record | Buy | $18.8K | conv 18 | SEC |
| HASSAN FREDtrack record | AwardD (derivative) | $1M | Unusual size | SEC |
| FROST PHILLIP MD ET ALtrack record | Award | $500K | SEC |
| Martin James Joseph | Award | $5K | SEC |
| PFENNIGER RICHARD C JRtrack record | AwardD (derivative) | $55.6K | SEC |
| HASSAN FREDtrack record | Award | $500K | Unusual size | SEC |